This Article  • Abstract  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Renal Diseases, Other  • Review  • Alert me on articles by topic  Social Bookmarking   What's this?

Henry T. Yu, MD

Arch Intern Med. 2003;163:1417-1429.

ABSTRACT
Chronic renal failure is characterized by a persistently abnormal glomerular filtration rate. The rate of progression varies substantially. Several morphologic features are prominent: fibrosis, loss of native renal cells, and infiltration by monocytes and/or macrophages. Mediators of the process include abnormal glomerular hemodynamics, hypoxia, proteinuria, hypertension, and several vasoactive substances (ie, cytokines and growth factors). Several predisposing host factors may also contribute to the process. Treatments to delay progression are aimed at treating the primary disease and at strictly controlling the systemic blood pressure and proteinuria. The role of antihypertensive agents, statins, and use of other maneuvers such as protein restriction and novel approaches are also discussed herein.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

Chronic renal failure is characterized by a persistently abnormal glomerular filtration rate (GFR). It represents an evolving process that is initiated by various causes, all with the common end result of persistent and usually progressive damage of varying severity to the kidneys. However, the rate of decline, often referred to as progression, can vary substantially. The present article will discuss processes that affect progression after the initial renal insult has occurred.

Chronic renal failure is a common problem. In the third National Health and Nutrition Examination Survey done from 1988 to 1994, 3% of the US adult population was found to have elevated serum creatinine values.¹ Once the renal failure is well established, the rate of progression can be estimated, although limitations exist.^2-9

Many features are common to progression of renal failure of various causes, and the final histologic appearance is one of glomerulosclerosis, interstitial fibrosis, and loss of native renal cells. Nevertheless, the causes of chronic renal failure are heterogeneous, and the mechanisms and locations of the initial injury may vary. Different animal models emphasize different aspects of the pathophysiologic characteristics and only incompletely replicate clinical disease.

MORPHOLOGIC CHANGES

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

Several morphologic features are prominent: fibrosis; loss of normal renal cells, mainly by apoptosis; and infiltration by monocytes and/or macrophages. These represent the end result of the constant interplay between vasoactive substances (ie, cytokines and growth factors).

Impairment of renal function correlates better with the extent of tubulointerstitial injury than with histologic glomerular injury.¹⁰ Interstitial fibrosis results from increased synthesis and decreased breakdown of extracellular matrix (ECM). The abnormal ECM contains an excess of normal components such as fibronectin, laminin, proteoglycans, and type IV collagen. Apart from the evident histologic changes, alterations in the ECM composition also change the ways the cells interact with the ECM, and these in turn affect gene regulation in response to specific growth factors. The details remain an active area of inquiry.¹¹

Myofibroblasts (cells containing features of smooth muscle cells and of fibroblasts) are involved in the fibrogenic process and can secrete alpha 2(I) and alpha 2(III) collagens and fibronectin. Their origins vary because several types of intrarenal cells can transdifferentiate into myofibroblasts.^12-13 Moreover, in animal models, injured tubular cells also contribute to the development of interstitial fibrosis.¹⁴

Physiologic cell death is a normal event in tissue homeostasis and is important for removal of unnecessary or damaged cells. In the context of renal disease, the balance between cell proliferation and apoptosis plays a critical role in maintaining an optimal number of cells after an insult.^15-16 In chronic renal failure, there is a loss of normal resident cell population thought to be caused by a combination of abundant proapoptotic stimuli and diminished antiapoptotic stimuli. Examples of the former are transforming growth factor (TGF-), tumor necrosis factor (TNF), Fas ligand (FasL), and interferon . At the same time, the normal ECM, probably through interaction with cell-surface -integrin receptors, inhibits apoptosis. Because the normal ECM becomes replaced by an abnormal one, its antiapoptotic effect is lost.^17-18 The end result is a decreased population of the normal glomerular and tubular epithelial cells.

The Fas apoptosis pathway is initiated by the binding of FasL to Fas, which triggers a cascade of intracellular signals that results in apoptotic deletion of Fas-bearing target cells.¹⁹ Fas and FasL are constitutively expressed in renal tubular cells.^20-21 Animal studies suggest that up-regulation of Fas in the tubules in response to cytokines favors its binding to FasL located on adjacent cells and thus leads to apoptosis.^21-22 Tissue hypoxia from decreased perfusion of the microvasculature in chronic renal failure also stimulates Fas-mediated apoptosis.²³ In addition, podocyte apoptosis may play an early role in progression of diabetic nephropathy and in focal segmental glomerulosclerosis.^24-26

Monocytes and/or macrophages are recruited by cytokines, which are overexpressed in chronic renal failure. As a response to injury, overexpression of macrophage-colony stimulating factor by the tubules drives local macrophage proliferation in the kidney.²⁷ Plasma levels of neopterin, a marker of monocyte activation, increase progressively with worsening clinical renal function.²⁸ Macrophage infiltration in the interstitium correlates with the degree of renal dysfunction.^29-31 These cells amplify the response by producing more cytokines, which promote further fibrosis and apoptosis.^{16, 27} Treatment modalities that decrease chemotaxis ameliorate renal failure.³² Experimentally, macrophage-derived cytokines, including interleukin (IL) 1, IL-6, and TNF-, inhibit expression of vascular endothelial growth factor (VEGF); this is probably partly responsible for impaired angiogenesis and capillary loss.³³ Recently, mast cells in the interstitium have been found to correlate with severity of interstitial fibrosis in patients with various glomerulonephritides.³⁴ That there is also association with its growth factor and myofibroblasts suggests that these cells may be involved in progression of interstitial fibrosis as well.³⁴

MEDIATORS OF INJURY

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

For purposes of the present discussion, mediators are factors and processes that perpetuate renal dysfunction after an initial insult of sufficient severity has occurred. They usually occur as a consequence, no matter how remote, of the initial renal damage (Figure 1).

View larger version (19K): [in this window] [in a new window] Pathophysiologic pathway of chronic renal failure.

Hemodynamics

In rats subjected to subtotal nephrectomy, compensatory hyperfiltration of the spared nephrons helps to maintain overall GFR. However, this adaptation also leads to glomerular hypertension, proteinuria, and progressive chronic renal failure.³⁵ The stretching of the capillary tuft also stretches the adjacent mesangial cells, which induces mesangial cell proliferation and glomerulosclerosis at least partly by overexpression of cytokines such as platelet-derived growth factor (PDGF)³⁶ and monocyte chemoattractant protein 1.³⁷

Early diabetic nephropathy is well known to be associated with an elevated GFR.^38-40 Experimentally, increased glomerular capillary hydraulic pressure and hyperfiltration occur (despite normal systemic pressures) due to a proportionally greater reduction in the afferent relative to efferent arteriolar resistance.⁴¹ Indirect measurements suggest that glomerular capillary hypertension is present in human patients with diabetes as well, and there is also a correlation between urine albumin excretion and the glomerular pressure but not systemic pressure. Thus, as in the remnant kidney model, the glomerular hypertension in diabetic nephropathy itself propagates chronic GFR decline, at least partly by increasing protein leakage across the glomerular capillaries into the Bowman space.⁴² Apart from increased glomerular capillary hydraulic pressure, cytokines activated by injury may counteract tonic mesangial cell contraction and also contribute to hyperfiltration.⁴³

Hyperfiltration has not been well studied in nondiabetic human renal disease, and the extent to which this occurs in humans is not known for certain. Keller et al⁴⁴ recently found that white hypertensive patients have fewer but larger glomeruli, suggesting compensatory hyperfiltration. Modeling of human lupus nephritis also suggests that hyperfiltration occurs and is indeed beneficial, at least in the short term.⁹ Studies of patients who have undergone unilateral nephrectomy have shown no deterioration in renal function.^45-47 However, there may be a critical renal mass below which hyperfiltration becomes detrimental. Patients with greater than 50% loss of renal mass have been shown to have a long-term increased risk for proteinuria and renal insufficiency.⁴⁸

Hypoxia

Hypoxia has been regarded as a potential cause as well as effect of progression. There is loss of the postglomerular intertubular capillaries in chronic renal failure of various causes.⁴⁹ Glomerular sclerosis is thought to contribute to this by decreasing downstream tubular blood flow. Expansion of the interstitial space may also diminish capillary perfusion of the tubules.⁵⁰ The resultant hypoxia favors release of proinflammatory and profibrotic cytokines. Experimentally, this is associated with increased expression of the antiangiogenic factor thrombospondin 1 and decreased expression of the proangiogenic factor VEGF, which may impair angiogenesis and further propagate the hypoxia.³³

Cellular hypoxia prevents degradation of the transcription factor hypoxia-inducible factor 1, which then becomes available to bind to hypoxia-response elements in genes that are switched on by hypoxia.⁵¹ One such hypoxia-response element has been found in the tissue inhibitor of metalloproteinase 1 promoter.⁵² Apart from this, hypoxia has been found to increase expression of endothelin (ET) 1⁵³ and collagen alpha 1(I) and to decrease expression of collagenase.⁵² Tubular hypoxia also favors expression of Fas in the tubular cell membrane and apoptosis.²³

Proteinuria

Proteinuria occurs as a result of glomerular capillary hypertension and damage to the permeability barrier in the glomerulus. Protein leaking across the glomerulus is taken up by the proximal tubule cells by endocytosis. This causes protein overload on the proximal tubular cells, leading to increased activation of the intrarenal angiotensin-converting enzyme (ACE)⁵⁴ and also, either directly or via activation of transcription factors,⁵⁵ to abnormal production of the following cytokines: ET-1, monocyte chemoattractant protein 1, and RANTES (regulated on activation, normal T-cell expressed and secreted).⁵⁶ The cytokines favor fibrosis, apoptosis, and monocytic infiltration, further propagating the process.

In proteinuric animals, there is also direct translocation of growth factors such as TGF- and hepatocyte growth factor directly from plasma into tubular fluid. These then interact with receptors located at the apical membrane of tubular cells to promote interstitial fibrosis.^57-58

Specific protein metabolites may also be involved in the progression of chronic renal failure. Indoxyl sulfate, one such metabolite, has been shown to increase glomerulosclerosis in animals⁵⁹ by increasing renal TGF- synthesis, both directly and by promoting the expression of intercellular adhesion molecule 1, the latter leading to monocyte infiltration.⁶⁰ Elevated urinary levels of this metabolite also correlate with a more rapid progression in humans.⁶¹ Animal and human studies have shown decreased serum and urinary indoxyl sulfate levels by using AST-120, an oral adsorbent.^62-63

In the presence of impaired glomerular permeability, transferrin in association with iron also enters the tubular lumen and is taken up by the proximal tubule cells. Such accumulation has been demonstrated in human chronic renal disease.⁶⁴ In vitro evidence using human proximal tubular epithelial cells indicates that iron-mediated lipid peroxidation⁶⁵ and complement activation by the apotransferrin component⁶⁶ contribute to toxic effects.

Consistent with its role in pathophysiology, proteinuria is a strong predictor of clinical progression of renal disease. The rapidity of GFR decline is proportional to the severity of proteinuria.⁶⁷

Systemic Hypertension

Systemic hypertension is a frequent accompaniment to chronic renal disease. Sodium, volume excess, and activation of the renin-angiotensin-aldosterone system in patients with chronic renal failure all cause hypertension. In addition, afferent stimuli from the kidneys may activate the sympathetic nervous system and contribute to the elevated pressure.⁶⁸ Hypertension itself accelerates decline in renal function,^69-71 likely due to the associated increased glomerular capillary hypertension.

Complement Activation

There is at least 1 animal model in which proteinuria is ameliorated by inhibition of complements.⁷² Clinically, patients with proteinuria have been shown to excrete complement degradation products into the urine.⁷³ Because of abnormal glomerular permeability, complement can enter the tubular lumen and initiate formation of the C5b-9 membrane attack complex.⁷⁴ Exposure of tubular cells to an unidentified component of serum protein have also been shown to cause increased synthesis and release of complements by the cells themselves, predominantly toward the basolateral component.⁷⁵ It has also been suggested that hyperammoniagenesis resulting from intratubular catabolism of excessive protein load also leads to complement activation and consequent interstitial scarring.⁷⁵

Angiotensin II

Angiotensin II (AII) is formed by progressive cleavage of angiotensinogen. The kidneys contain all the machinery necessary to generate AII locally.⁷⁶ This local intrarenal renin-angiotensin system is regulated independently of the systemic one and plays a critical role in renal autoregulation and pathophysiologic developments.⁷⁷ Enhanced sensitivity to effects of locally produced AII is present in diabetic rats⁷⁸ and has been postulated in an animal model of nondiabetic renal failure.⁷⁹

Apart from its hemodynamic effects, AII also stimulates expression of fibronectin⁸⁰ and several other downstream cytokines and growth factors that favor fibrogenesis and recruitment of macrophages. Examples are TGF-, plasminogen activator inhibitor 1 (PAI-1), aldosterone, ET,⁸¹ osteopontin,⁸² and possibly the transcription factor nuclear factor B.⁸³

Other Chemical Mediators

As noted above, a growing list of vasoactive substances (ie, cytokines and growth factors) have been shown to be involved in progression of renal disease^84-95 (Table 1). Cytokines and growth factors gain access to the kidneys by multiple pathways. They can be synthesized elsewhere and be ultrafiltered across the glomeruli and act on tubular cells through apical receptors.⁵⁷ They can also be secreted by resident renal cells in response to various stimuli and by infiltrating monocytes. Moreover, chemical mediators probably do not act in isolation; they often mediate the expression or release, or modulate the effect, of other mediators.^96-98 There is overlap,⁵⁷ and the net effect can can be either beneficial or detrimental, depending on the physiologic context. There is also no universal agreement on the overexpression and underexpression of all cytokines among different models of renal disease studied by various investigators.

View this table: [in this window] [in a new window] Table 1. Selected Cytokines and Growth Factors Involved in Progression of Chronic Renal Failure

Transforming Growth Factor . Transforming growth factor is the most well-studied and probably the most significant of the fibrogenic cytokines. It is produced by resident renal cells and by infiltrating monocytes. Production is stimulated by various chemical stimuli such as AII, elevated plasma glucose, and IL-1,¹³ as well as by mechanical stretching of mesangial and renal tubular cells.⁹⁹ Directly and by increasing expression of other cytokines, TGF-1 favors deposition of new ECM and decreases its degradation. It also favors monocytic/macrophage infiltration, transdifferentiation of tubular cells into myofibroblasts,¹⁰⁰ and podocyte apoptosis.²⁵

Among the downstream cytokines affected by TGF-1 are PAI-1, hepatocyte growth factor, connective tissue growth factor, and nitric oxide. The causal role of this cytokine was evidenced by a recent study using an animal model of type 2 diabetes mellitus, in which chronic administration of a monoclonal antibody against TGF- prevented the development of renal insufficiency, expression of matrix components, and histologic changes.¹⁰¹

Plasminogen Activator Inhibitor 1. There are 2 major systems involved in degradation of ECM: the plasminogen system and the matrix metalloproteinases. Both systems are activated by tissue-type plasminogen activator. Not detectable in the normal kidney, PAI-1 is expressed in the chronically damaged kidney and inhibits the ability of tissue-type plasminogen activator to convert plasminogen to plasmin and tissue matrix metalloproteinases to the active form. In addition, PAI-1 may also inhibit the endothelial isoform of nitric oxide synthase and thereby locally decrease nitric oxide production.

Expression of PAI-1 is increased by AII, angiotensin IV,^102-103 TGF-,¹⁰⁴ and aldosterone.¹⁰⁵ Serum samples from patients with azotemia have been shown to favor cytokine-induced secretion of PAI-1.¹⁰⁶ It has also been hypothesized that there may normally be a tonic inhibition of PAI-1 transcription involving cell-matrix interaction. Loss of this inhibition, mediated either by cytokines or by loss or change of the normal matrix,¹⁰⁷ favors ECM deposition.

Nitric Oxide. Nitric oxide is formed by the oxidation of L-arginine into L-citrulline. Three isoforms of the nitric oxide synthase catalyze this reaction: constitutive endothelial nitric oxide synthase, neuronal nitric oxide synthase, and inducible nitric oxide synthase. Nitric oxide inhibits mesangial cell proliferation and ECM synthesis and may limit capillary permeability. In rat models, nitric oxide inhibition results in proteinuria,^{79, 108} increased blood pressure, and decreased GFR independent of renal AII levels.⁷⁹ Collagen I expression is also increased, independent of systemic hemodynamics.⁸¹ It has been suggested that nitric oxide inhibits collagen I expression in the renal vasculature, and the detrimental effects of endogenous AII are increased in states of low nitric oxide availability. A polymorphism of the endothelial nitric oxide synthase gene has been described and found to be associated with development of diabetic nephropathy, suggesting that the associated lower mean plasma nitric oxide level may translate into decreased suppression of ECM synthesis.¹⁰⁹

Total nitric oxide production has been shown to be low in chronic renal failure in most, but not all, studies. The major source of endogenous arginine is normally the proximal tubules. Whole-body L-arginine synthesis of arginine remains normal in hemodialysis patients¹¹⁰ and may reflect compensatory extrarenal synthesis. The extent to which local arginine availability may affect nitric oxide production locally is unclear. Parathyroid hormone, which is elevated in chronic renal failure, down-regulates nitric oxide synthase expression.¹¹¹ Various substances overexpressed in renal failure (PAI-1,¹¹² asymmetric dimethylarginine,¹¹³ PDGF,¹¹⁴ TGF-,¹¹⁵ and ET-1¹¹⁶) can inhibit nitric oxide synthase, thereby diminishing conversion of L-arginine to nitric oxide. In patients with diabetes, scavenging of formed nitric oxide by advanced glycosylation end products may also contribute to the decreased nitric oxide levels.

On the other hand, cytokines activated by injury may inappropriately activate inducible nitric oxide synthase.¹¹⁷ It has been proposed that the resultant relaxation of tonic mesangial cell contraction leads to hyperfiltration and contributes to progression of renal failure.⁴³

Aldosterone. Aldosterone levels are often elevated in normokalemic patients with chronic renal failure.^118-119 Animal studies suggest that aldosterone may mediate progression of chronic renal failure.¹²⁰ Subtotal nephrectomy in rats results in adrenal hypertrophy and elevation of plasma aldosterone level. Arterial hypertension, proteinuria, and glomerulosclerosis develop; these are ameliorated by the combination of an angiotensin receptor blocker (ARB) and an ACE inhibitor. Infusion of exogenous aldosterone restores the deleterious effects of subtotal nephrectomy, despite the concomitant administration of the ARB and the ACE inhibitor.¹²⁰ These can be prevented by adrenalectomy.¹²¹

Aldosterone has also been shown to up-regulate ACE messenger RNA expression in cultured neonatal rat cardiocytes, thus completing a positive feedback mechanism.¹²² Aldosterone increases PAI-1 expression and may induce renal injury through this mechanism.^{105, 123} Alternatively, there is experimental evidence that aldosterone may mediate renal vascular damage independent of its effects on blood pressure.^124-125 It has been hypothesized that fibrosis may then be a secondary effect of the vascular damage.¹²⁵

Endothelin. The ET system consists of 2 receptors, 3 ligands, and 2 activating peptidases. The 2 mammalian receptors are labeled ET_A and ET_B. The 3 ligands are ET-1, ET-2, and ET-3. All are constitutively synthesized and released by glomerular and tubular cells. Endothelin expression is favored by AII,¹²⁶ IL-1, TGF-, glucose, and hypoxia,⁵³ among others.

Several actions mediated by ET may play a role in the progression of renal failure: blockage of inducible nitric oxide synthase transcription via the ET_A receptor; increased expression of the collagen 1 gene⁸¹; vascular remodeling¹²⁷; mediation of proteinuria¹²⁸; macrophage chemotaxis; and stimulation of interstitial fibroblast proliferation and ECM synthesis. Endothelin may also mediate renal activation of nuclear factor B, which in turn regulates the transcription of other genes involved in renal injury.⁸³ Experimentally, the use of an ET receptor antagonist in combination with an ACE inhibitor improves proteinuria and histologic changes beyond what occurs with either agent alone. This suggests that ETs play a role in at least some animal models.^{83, 129} In the rat subnephrectomy model, blockade of the ET_A receptor reduces proteinuria more than does nonselective blockade.¹³⁰ It has also been shown that the ET_A receptor, but not the ET_B receptor, mediates salt sensitivity of AII-induced hypertension in the rat.^{126, 131}

Platelet-Derived Growth Factor BB. Platelet-derived growth factor has been implicated in the progression of renal injury. It stimulates mesangial proliferation and increases ECM synthesis. Furthermore, overexpression of this cytokine, as well as its receptor, in the glomeruli and tubular and interstitial compartments has been demonstrated experimentally.^{94, 132} Levels of PDGF are increased in response to AII, lipoproteins, ET, and other cytokines.

Two chains, PDGF-A and PDGF-B, form the active homodimers or heterodimers. Experimentally, PDGF-BB, but not PDGF-AA, induces renal myofibroblast transdifferentiation and tubulointerstitial fibrosis.¹³³ Platelet-derived growth factor BB has also been shown to increase the expression of type III collagen by tubular cells and by myofibroblasts.^{57, 134} In rat anti-Thy1.1 nephritis (a model of mesangioproliferative glomerulonephritis), transient antagonism of PDGF after disease induction prevented development of glomerulosclerosis, tubulointerstitial damage, and collagen accumulation.¹³⁵

PREDISPOSING FACTORS

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

Numerous host factors have been associated with progression of renal failure. The most important ones are discussed below.

ACE Gene Polymorphism

A 287–base-pair fragment in intron 16 in the ACE gene can either be present (the I allele) or absent (the D allele). Presence of the D allele is associated with elevated systemic ACE levels while the I allele is associated with the opposite effect. Both alleles are codominant such that the 3 resulting genotypes (II, ID, and DD) are associated with low, intermediate, and high amounts of circulating ACE, respectively. This relationship holds true for intrarenal ACE as well.¹³⁶

The D allele has been found in numerous studies to be either indifferent or deleterious to the progression of renal failure, as noted in a recent review.¹³⁷ A study in patients with IgA nephropathy indicated that the risk associated with the D allele was most apparent in patients without proteinuria or hypertension, suggesting a weaker effect compared with these 2 risk factors.¹³⁸

There remains controversy as to whether the presence of the D allele affects response to antiproteinuric therapy with ACE inhibitors. Conclusions from retrospective studies on nondiabetic nephropathy are divided, with some finding a poorer response with the I allele, and others with the DD genotype.¹³⁷ A prospective study on type 1 diabetes mellitus has shown better response of albuminuria to ACE inhibitor treatment among those with the II genotype.¹³⁹

Other polymorphisms have also been studied, albeit to a lesser extent than that involving the ACE gene. Examples include the angiotensinogen M235T polymorphism, the chymase gene CM A/B polymorphism, and the angiotensin receptor A1166C polymorphism.¹⁴⁰ Of these, the M235T polymorphism is thought to contribute to risk of developing chronic renal failure, though this remains undefined.¹⁴⁰

Smoking

Smoking has been found to be associated with progression in diabetic nephropathy,^141-142 primary renal disease,¹⁴³ and severe hypertension.¹⁴⁴ Smoking is a risk factor for proteinuria independent of the presence of diabetes and blood pressure¹⁴⁵ and may contribute to progression because of the associated proteinuria. Elevation of ET-1 levels¹⁴⁶ and acceleration of atherosclerosis and ischemic nephropathy¹⁴⁷ may also be contributory. There are no prospective studies addressing whether smoking cessation ameliorates progression of renal failure.

African American Descent

In a prospective cohort study of previously untreated nondiabetic men with hypertension enrolled in the Multiple Risk Factor Intervention Trial (MRFIT), effective blood pressure control was associated with stable or improving renal function in nonblacks but not in blacks.¹⁴⁸ A subsequent article¹⁴⁹ involving all participants of the above MRFIT study found an increased risk of end-stage renal disease among blacks independent of several other factors. Analysis of the baseline characteristics of the Modification of Diet in Renal Disease study also identified black race as an independent predictor of a faster GFR decline.¹⁵⁰

Socioenvironmental factors and genetic background have been proposed to account for the tendency toward excessive disease progression in African Americans. Part of the greater susceptibility may be from increased cytokine activation: ET-1¹⁵¹ and TGF-¹⁵² levels have been found to be more elevated in African Americans with hypertension than in their white counterparts.

Diabetes Mellitus

Men with diabetes have been found to have a higher incidence of end-stage renal disease ascribed to nondiabetic causes, even after accounting for age, ethnicity, income, blood pressure, cholesterol, and history of coronary artery disease.¹⁵³

Male Sex

Various studies have suggested that nondiabetic renal diseases progress more rapidly in men.^154-158 However, the studies vary widely in design and methodology. Not all studies have clearly shown the effect of sex to be independent of other factors such as proteinuria, severity of hypertension, and smoking history. Various mechanisms have been reviewed elsewhere^159-160 and include increased response to AII in men¹⁶¹ and estradiol's ability to reverse TGF-1–mediated fibrogenesis.¹⁶²

Hyperlipidemia

Chronic renal failure is associated with elevation of triglyceride levels, oxidized low-density lipoprotein, lipoprotein (a), and decreased apolipoprotein (a). Renal failure itself may also promote hyperlipidemia by down-regulating the expression of the enzyme lecithin:cholesterol acyltransferase in the liver and its activity in the plasma.¹⁶³

Experimentally, hypercholesterolemia and hypertriglyceridemia can each promote proteinuria and tubulointerstitial injury,¹⁶⁴ while treatment aimed at decreasing lipid levels ameliorates the rate of progression.¹⁶⁵ Putative mechanisms of damage include stimulation of reactive oxygen species, inhibition of nitric oxide, modulation of mesangial growth and proliferation, monocyte infiltration,³² and stimulation of growth factor and cytokine release.^166-168

In humans, various lipid abnormalities have been associated with the development of new renal insufficiency¹⁶⁹ and progression of established renal disease.^{150, 170} However, a definite causal relationship is equivocal. Moreover, the component(s) of the dyslipidemic milieu most responsible for progression is not clearly defined.^{169, 171} Elevation of total cholesterol levels, low high-density lipoprotein, elevated triglyceride levels, and apolipoprotein B–containing lipoproteins have all been implicated.^{169, 172-173}

Recreational Drug Use

The use of heroin and other opiates¹⁷⁴ and of cocaine has been found to be associated with increased risk for development of end-stage renal disease.¹⁷⁵ Cocaine use may exacerbate hypertensive nephrosclerosis through progression of renal ischemia. It is unclear whether heroin and opiate use is causally related to the increased risk or represent only a surrogate marker.

Prenatal Factors

Animal studies have shown a decrease in glomerular number with induced intrauterine malnutrition¹⁷⁶ but not with spontaneous low birth weight.¹⁷⁷ In humans, the number of glomeruli correlates directly with the birth weight.¹⁷⁸ There is also a direct correlation between low birth weight and chronic renal disease, which appears to hold true across races.^179-181 While a resultant lowered renal reserve and any possibly compensatory glomerular capillary hypertension might theoretically accelerate progression to end-stage renal disease, it is not yet clear if the low birth weight itself is directly responsible for the increased incidence of chronic renal failure because hypertension^182-183 and diabetes^183-184 are also associated with retardation of intrauterine growth.¹⁸⁵

TREATMENT

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

The major steps involved in slowing the progression of renal failure are outlined in Table 2. More detail is provided below.

View this table: [in this window] [in a new window] Table 2. Maneuvers to Slow the Progression of Chronic Renal Disease

Treatment of Underlying Disease

Treatment of some causes retards progression to chronic renal failure. Experimentally, antagonism of PDGF during the acute phase of an animal model of mesangioproliferative nephritis prevented functional and morphologic changes of chronic renal failure from developing.¹³⁵ Clinically, this may involve treatment of acute disease, although this is not invariable. For example, even in established chronic diabetic nephropathy, euglycemia of 10 years' duration following pancreatic transplantation has been shown to reverse histologic renal lesions.¹⁸⁶

At the other extreme, there is encouraging if early evidence that at least in some animal models, more specific downstream therapy may be useful for well-established chronic disease. Examples include use of relaxin (which decreases macrophage infiltration and interstitial fibrosis independent of hemodynamic effects¹⁸⁷), VEGF,¹⁸⁸ and aldosterone antagonists.¹⁸⁹

Treatment of Hypertension

The renal benefit of treatment depends to a significant extent on the underlying proteinuria. This was borne out in the Modification of Diet in Renal Disease study, which consisted of 2 randomized clinical trials. Study 1 evaluated patients with GFRs of 25 to 55 mL/min, while study 2 evaluated patients with GFRs of 13 to 24 mL/min. In both studies, patients were randomized to groups with mean arterial pressure (MAP) goals of either 92 mm Hg or 107 mm Hg. The decline in GFR was found to be slower in the more aggressively treated group overall, and the benefit was in direct proportion to the severity of the baseline proteinuria.¹⁹⁰

In renal disease from type 1 diabetes mellitus, tighter blood pressure control, independent of use of ACE inhibitors, decreases proteinuria.¹⁹¹ A recent study from the Steno Diabetes Center showed that tight blood pressure control (MAP goal of 93 mm Hg) in this population can decrease the GFR decline to that found with normal aging.¹⁹²

The UK Prospective Diabetes Study (UKPDS) and the Hypertension Optimal Treatment (HOT) study suggest that blood pressure can be aggressively yet safely lowered. The UKPDS showed a linear relationship between blood pressure and microvascular disease in patients with type 2 diabetes mellitus. This held true for average systolic blood pressures at least as low as 114 mm Hg.¹⁹³ The HOT study showed that treating the blood pressure to as low as 120/70 mm Hg was not associated with any increase in cardiovascular events or mortality. Moreover, in the subset of patients with diabetes, cardiovascular events and mortality were lowest in the group assigned to a target diastolic blood pressure of 80 mm Hg or lower.¹⁹⁴

Thus, to slow down GFR decline, the goal for patients without diabetes with significant proteinuria involving at least 1 g/d and for patients with diabetes is to lower the MAP to the low 90s. Based on the Modification of Diet in Renal Disease study data, Peterson and coworkers¹⁹⁵ have suggested a MAP goal of 98 mm Hg or lower for patients with proteinuria involving between 0.25 and 1 g/d.

Treatment of Proteinuria

ACE Inhibitors. As many of the pathophysiologic changes associated with chronic renal disease are driven by AII, ACE inhibitors have become the logical and accepted choice for treatment. ACE inhibitors block the rate-limiting step in the formation of AII. Benefits have been shown in experimental and clinical settings. These drugs preferentially dilate the efferent arteriole, thereby hemodynamically decreasing glomerular hypertension and proteinuria.^196-197 They also decrease proteinuria by preserving the integrity of component proteins of the slit diaphragm^198-199 and by ameliorating podocyte foot process broadening.²⁰⁰

Numerous other salutary effects have been found. Experimentally, ACE inhibitors ameliorate monocyte/macrophage infiltration, TGF- expression, fibroblast proliferation, differentiation into myofibroblasts,²⁰¹ and development of interstitial fibrosis.²⁰² Inhibition of at least some of these AII-mediated cytokine releases is probably due to decreased TGF-1, which has been shown in patients treated with ACE inhibitors.^203-204

Clinical benefits have been found for diabetic and nondiabetic renal disease.^{67, 205-207} In patients with diabetes, ACE inhibitors prevent progression of microalbuminuria, even in patients with controlled blood pressure. In a European study on type 1 diabetes mellitus, mean baseline systolic and diastolic blood pressure in the group randomized to receive lisinopril were 122 and 79 mm Hg, respectively. Adjustment for effects of systolic and diastolic blood pressure reduced, but did not eliminate, this benefit.²⁰⁶ A meta-analysis of 12 studies involving type 1 diabetes mellitus also came to the same conclusion.²⁰⁸

Even in the presence of chronic renal insufficiency, ACE inhibitors can be used.^{207, 209-210} The benefits are proportional to the extent of proteinuria.^{67, 210} Improvement in proteinuria is evident within the first 2 months.^{67, 211} The preservation of GFR is directly proportional to the extent of lowering of proteinuria, which thus serves as a useful prognostic indicator.^{67, 212}

Angiotensin Receptor Blockers (ARBs). Because ACE can be formed by non–ACE-dependent pathways and because of intolerance to ACE inhibitors in many patients, ARBs have been increasingly used to delay progression of renal damage. Experimentally, ARBs have been shown to block fibroblast proliferation and synthesis of TGF-.²⁰¹ As in the case of ACE inhibitors, multiple mechanisms are responsible for the antiproteinuric effect. Angiotensin receptor blockers block expressions of cytokines like VEGF.²¹³ They also have been found to normalize the glomerular nephrin deficiency²¹⁴ and podocyte foot process broadening in diabetic animals.^{200, 214} Animal studies suggest that the benefits are similar to those of ACE inhibitors.^{198, 214}

Recent clinical trials have shown that these agents diminish proteinuria^215-217 and protect against renal function decline among patients with type 2 diabetes mellitus and nephropathy.^215-216 The 2 largest studies have been done on patients with relatively mild azotemia. However, results from studies using ACE inhibitors suggest that ARBs may be beneficial even in patients with more advanced chronic renal failure.

No large-scale comparative studies have been published comparing ARBs and ACE inhibitors regarding progression of chronic renal failure. However, small studies suggest comparable benefits in antiproteinuric effects,^218-219 and no differences in rate of progression were found in a study of diabetes mellitus at 1 year.²²⁰ Animal data indicate that the combination results in better reduction of renal AII levels than either agent alone.²²¹ Clinical studies have been conflicting as to whether a combination of both agents has additive antiproteinuric effects.^{218, 222-223} However, the addition of ARBs to maximal ACE inhibition may reduce renal TGF-1 production despite the lack of salutary effects on proteinuria.^223-224 Unfortunately, no large prospective studies on rate of progression using combination therapy are currently available.

Calcium-Channel Blockers. Dihydropyridines do not have antiproteinuric effects.^{210, 225} Nondihydropyridines, in contrast, appear to have some role, at least in diabetic nephropathy.^226-227 There are no good data on its usage in nondiabetic nephropathies for retarding progression of renal disease, although plans for a multicenter study were recently published to investigate combined treatment with an ACE inhibitor and either a dihydropyridine or a nondihydropyridine calcium channel blocker, using proteinuria as an end point.²²⁸

-Blockers. Though smaller studies had suggested that -blockers may worsen the decline of GFR in patients with diabetes,^{227, 229} the larger UKPDS-39 study found atenolol and captopril to be equivalent in limiting progression of albuminuria and azotemia over 4 years.²³⁰ Interestingly, a recent animal study found that blocking the sympathetic nervous system may be beneficial independent of antihypertensive effects.²³¹ In a multicenter prospective study of nondiabetic African Americans with hypertensive renal disease, metoprolol was comparable with ramipril in reduction of proteinuria and in progression to end-stage renal disease.²³² However, a composite end point and the overall rate of GFR decline was worse with metoprolol, suggesting that ACE inhibitors should still be the preferred agents in this population.

Protein Restriction

The role of protein restriction remains controversial. The largest prospective study to evaluate the role of protein restriction in retarding progression of renal disease failed to show a significant benefit.¹⁹⁰ Subsequent secondary analysis of the data revealed a correlation between decreased protein intake and slower progression.²³³

Two relatively recent meta-analyses of low-protein studies have been performed.^234-235 In both, nondiabetic patients with chronic renal failure were shown to benefit from protein restriction. However, it appears that the difference in rate of decline of GFR is small. Pooling the results of 13 randomized control trials, Kasiske et al²³⁵ estimated a difference of only 0.53 mL/min per year among those assigned to protein restriction, which may not be clinically meaningful. For diabetic chronic renal disease, the benefits seemed greater, but the pooled number of patients was small, totaling only slightly over 100 in both meta-analyses.

A caveat has to be noted. It has been shown that a low-protein diet decreases the filtered urine creatinine as well as urine creatinine secretion and affects the latter more than the former. Such changes can occur independent of changes in the GFR.⁸

In the clinical trial setting, at least, low-protein diets have been safe and have not been associated with hypoalbuminemia or other evidence of worsening malnutrition.^{190, 236-237} Whether this is replicable outside of a research environment remains to be seen. It also remains unclear whether there is benefit in combining a low-protein diet with use of ACE inhibitors.

For patients with advanced renal failure (GFR <25) who are not undergoing dialysis, the K/DOQI guidelines²³⁸ currently recommend protein restriction to 0.6 g/kg per day, but allowing for a maximum of 0.75 g/kg per day. While this avoids generation of nitrogenous metabolites and ameliorates uremic manifestations, an outright benefit in delaying progression remains unproven.

Treatment of Hyperlipidemia/Use of Statins

Most of the studies have used statins directed at lowering cholesterol,²³⁹ although some work has also been published on the use of triglyceride-lowering agents.²⁴⁰ Apart from their lipid-lowering effects, statins also have other actions that may ameliorate the progression of chronic renal failure. Statins down-regulate TGF- expression,²⁴¹ interfere with intracellular signaling pathways,²⁴¹ and prevent the activation of nuclear factor B and substances downstream of TGF- such as mitogen-activated protein kinases and connective tissue growth factor. Statins also possess antioxidant activity²⁴² and some antihypertensive effect.²⁴³ A recent meta-analysis of trials that were mostly based on statins showed a modest benefit in slowing down GFR decline.²³⁹

Aldosterone Antagonism

In vitro, in the presence of AII, aldosterone further increases PAI-1 expression.¹⁰⁵ This raises the possibility that aldosterone antagonism may have additional benefits beyond those of AII antagonism. Moreover, aldosterone suppression by ACE inhibitors alone may not be sustained.²⁴⁴ In different models of renal failure, however, aldosterone antagonism only partially reverses some, but not all, of the deleterious effects.^{120, 125, 245} A recently reported case series of 8 patients showed improvement in proteinuria by adding spironolactone to enalapril, though it is unclear if this occured independently of blood pressure changes.²⁴⁶

Erythropoietin

Erythropoietin receptors are present in the human kidney.²⁴⁷ It has thus been speculated that erythropoietin can exert cytokine effects on the kidneys and regulate their survival and proliferation.²⁴⁷ Apart from amelioration of hypoxia, this may have a salutary effect in progression of renal failure. Prospective clinical studies have been contradictory as to whether renal function is better preserved with erythropoietin.^248-249

Binding Protein Metabolites

Indoxyl sulfate is a protein metabolite that promotes the progression of glomerulosclerosis in animal studies. It was recently shown in a small study that AST-120, an oral adsorbent that binds indole (the precursor for indoxyl sulfate in the gut), decreases serum and urinary levels of indoxyl sulfate and also improves the rate of decline of GFR in patients with chronic renal failure.⁶²

Early Nephrology Referral

Studies on the effect of timing of nephrology referral on mortality have yielded conflicting results. However, late referral is associated with an increase in early morbidity.²⁵⁰ Specifically, early nephrology referral is associated with better predialysis care²⁵¹ and more appropriate choice of angioaccess for eventual hemodialysis.^251-252 It has also been found to be cost-effective.²⁵³

Other Modalities

Experimental Pharmacologic Agents. Endogenous atrial natriuretic peptide and brain natriuretic peptide cause vasodilation and natriuresis. The peptides are broken down by neutral endopeptidases. Since the active sites of neutral endopeptidases and ACE are structurally similar, vasopeptidases were developed to inhibit both enzymes.²⁵⁴ In animal studies, the vasopeptidase inhibitor omapatrilat was recently shown to be at least as efficacious as ACE inhibitors in decreasing proteinuria and glomerulosclerosis.^255-256

Peroxisome proliferator–activated receptor agonists are currently used to enhance insulin sensitivity in type 2 diabetes mellitus. Other effects apparently independent of plasma glucose have been reported. Salutary effects include amelioration of histologic changes in an animal model of this disease²⁵⁷ and in nondiabetic glomerulosclerosis.²⁵⁸ A short study has also shown improvement of microalbuminuria in diabetic patients.²⁵⁹

Experimentally, variable but often beneficial effects have been reported by blocking harmful cytokines and vasoactive substances such as PDGF,¹³⁵ ET,^{83, 260-261} TGF-,¹⁰¹ and epidermal growth factor.²⁶² Other studies have used cytokines such as relaxin,¹⁸⁷ hepatocyte growth factor,^263-264 and bone morphogenetic protein 7.²⁰² Antifibrotic agents^265-267 have also produced encouraging results.

Dietary Modification. Soy protein and flaxseed have shown benefit in some animal models.^268-271 Human studies are equivocal and are limited by small sample sizes and/or short follow-up. The longest prospective study to date, a crossover trial involving 6 months each of soy protein or animal protein, failed to show any change in GFR.²⁷² This topic has been recently reviewed.²⁷³

SUMMARY

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

Chronic renal failure is a common problem affecting a large number of people in the US population. Hemodynamic factors and various chemical mediators contribute to progression of chronic renal failure. Aggressive control of blood pressure and proteinuria, preferably with a regimen containing ACE inhibitors, remains the cornerstone of therapy. The role of protein restriction remains poorly defined but it does not appear to be generally useful. Statins may be useful. Novel agents and other modalities are at varying stages of development.

AUTHOR INFORMATION

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

Corresponding author and reprints: Henry T. Yu, MD, Primary Care and Subspecialty Medicine (111), William Jennings Bryan Dorn Veterans Affairs Medical Center, 6439 Garners Ferry Rd, Columbia, SC 29209 (e-mail: henry.yu{at}med.va.gov).

Accepted for publication August 30, 2002.

I would like to thank Mattie M. Ashford, RN, for her help with this article.

From the William Jennings Bryan Dorn Veterans Affairs Medical Center and the Division of Nephrology, Department of Medicine, University of South Carolina School of Medicine, Columbia. The author has no relevant financial interest in this article.

REFERENCES

Jump to Section  • Top  • Introduction  • Morphologic changes  • Mediators of injury  • Predisposing factors  • Treatment  • Summary  • Author information  • References

1. Coresh J, Wei L, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med. 2001;161:1207-1216. FREE FULL TEXT 2. Mitch WE, Walser M, Buffington GA, Lemann J Jr. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2:1326-1328. ISI | PUBMED 3. Rutherford WE, Blondin J, Miller JP, Greenwalt AS, Vavra JD. Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int. 1977;11:62-70. ISI | PUBMED 4. Muthusethupathi MA, Kumar SS, Sekaran L. Assessment of progression of chronic renal failure: using reciprocal of serum creatinine. J Assoc Physicians India. 1989;37:213-216. PUBMED 5. Kirschbaum BB. Analysis of reciprocal creatinine plots in renal failure. Am J Med Sci. 1986;291:401-404. ISI | PUBMED 6. Rowe PA, Richardson RE, Burton PR, Morgan AG, Burden RP. Analysis of reciprocal creatinine plots by two-phase linear regression. Am J Nephrol. 1989;9:38-43. ISI | PUBMED 7. Shah BV, Levey AS. Spontaneous changes in the rate of decline in reciprocal serum creatinine. J Am Soc Nephrol. 1992;2:1186-1191. ABSTRACT 8. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease study. J Am Soc Nephrol. 1996;7:556-566. ABSTRACT 9. Buckeit JB, Olshen RA, Blouch K, Myers BD. Modeling of progressive glomerular injury in humans with lupus nephritis. Am J Physiol. 1997;273(1, pt 2):F158-F169. 10. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease, II: the correlations. Hum Pathol. 1970;1:631-641. PUBMED 11. Yarwood SJ, Woodgett JR. Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation. Proc Natl Acad Sci U S A. 2001;98:4472-4477. FREE FULL TEXT 12. Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 1998;54:864-876. FULL TEXT | ISI | PUBMED 13. Fan JM, Huang XR, Ng YY, et al. Interleukin-1 induces epithelial-myofibroblast transdifferentiation through a transforming growth factor-1-dependent mechanism in vitro. Am J Kidney Dis. 2001;37:820-831. ISI | PUBMED 14. Suzuki T, Kimura M, Asano M, Fujigaki Y, Hishida A. Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat. Am J Pathol. 2001;158:75-85. FREE FULL TEXT 15. Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int. 1999;56:1199-1207. FULL TEXT | ISI | PUBMED 16. Savill JH. Regulation of glomerular cell number by apoptosis. Kidney Int. 1999;56:1216-1222. FULL TEXT | ISI | PUBMED 17. Sugiyama H, Kashihara N, Maeshima Y, et al. Regulation of survival and death of mesangial cells by extracellular matrix. Kidney Int. 1998;54:1188-1196. FULL TEXT | ISI | PUBMED 18. Mooney A, Jackson K, Bacon R, et al. Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via (1) integrin-mediated survival signals. Am J Pathol. 1999;155:599-606. FREE FULL TEXT 19. Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000;88:333-347. FULL TEXT | ISI | PUBMED 20. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415-429. ISI | PUBMED 21. Schelling JR, Cleveland RP. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int. 1999;56:1313-1316. FULL TEXT | ISI | PUBMED 22. Schelling JR, Nkemere N, Kopp JB, Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest. 1998;78:813-824. ISI | PUBMED 23. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest. 1999;79:1089-1099. ISI | PUBMED 24. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342-348. ISI | PUBMED 25. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF- and Smad7. J Clin Invest. 2001;108:807-816. FULL TEXT | ISI | PUBMED 26. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59:2104-2113. ISI | PUBMED 27. Isbel NM, Hill PA, Foti R, et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int. 2001;60:614-625. FULL TEXT | ISI | PUBMED 28. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 , TNF-, and their specific inhibitors in chronic renal failure and maintenance dialysis: relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154:882-892. ABSTRACT 29. Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int. 1987;31:964-972. ISI | PUBMED 30. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int. 1995;48:753-760. ISI | PUBMED 31. Yang N, Wu LL, Nikolic-Paterson DJ, et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant. 1998;13:1967-1974. FREE FULL TEXT 32. Nakao A, Nosaka K, Ohishi N, et al. Long-term effects of LTB4 antagonist on lipid induced renal injury. Kidney Int Suppl. 1997;63:S236-S238. PUBMED 33. Kang D, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model, I: potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434-1437. FREE FULL TEXT 34. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritis. Kidney Int. 2001;60:167-172. FULL TEXT | ISI | PUBMED 35. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93. 36. Kato H, Osajima A, Uezono Y, et al. Involvement of PDGF in pressure-induced mesangial cell proliferation through PKC and tyrosine kinase pathways. Am J Physiol. 1999;277:F105-F112. 37. Suda T, Osajima A, Tamura M, et al. Pressure-induced expression of monocyte chemoattractant protein-1 through activation of MAP kinase. Kidney Int. 2001;60:1705-1715. FULL TEXT | ISI | PUBMED 38. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93. ABSTRACT 39. Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 1992;41:829-835. ISI | PUBMED 40. Nelson RG, Tan M, Beck GJ, et al. Changing glomerular filtration with progression from impaired glucose tolerance to type II diabetes mellitus. Diabetologia. 1999;42:90-93. FULL TEXT | ISI | PUBMED 41. Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications. 1995;9:304-307. FULL TEXT | ISI | PUBMED 42. Imanishi M, Yoshioka K, Konishi Y, et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia. 1999;42:999-1005. FULL TEXT | ISI | PUBMED 43. Stockand JD, Sansom SC. Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol Rev. 1998;78:723-744. FREE FULL TEXT 44. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348:101-108. FREE FULL TEXT 45. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet. 1992;340:807-810. FULL TEXT | ISI | PUBMED 46. Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int. 1995;48:814-819. ISI | PUBMED 47. Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW. Forty-five year follow-up after uninephrectomy. Kidney Int. 1993;43:1110-1115. ISI | PUBMED 48. Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR. Long-term follow-up after partial removal of a solitary kidney. N Engl J Med. 1991;325:1058-1062. ABSTRACT 49. Bohle A, Muller GA, Wehrmann M, Mackensen-Haen S, Xiao JC. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl. 1996;54:S2-S9. PUBMED 50. Bohle A, von Gise H, Mackensen-Haen S, Stark-Jakob B. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli: functional interpretation of morphologic findings. Klin Wochenschr. 1981;59:1043-1051. FULL TEXT | ISI | PUBMED 51. Zhu H, Bunn HF. Signal transduction: how do cells sense oxygen? Science. 2001;292:449-451. FREE FULL TEXT 52. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000;58:2351-2366. FULL TEXT | ISI | PUBMED 53. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, Fine LG. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int. 1995;48:390-401. ISI | PUBMED 54. Largo R, Gomez-Garre D, Soto K, et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension. 1999;33:732-739. FREE FULL TEXT 55. Mezzano SA, Barria M, Droguett MA, et al. Tubular NF-B and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366-1377. FULL TEXT | ISI | PUBMED 56. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis. 2001;37(suppl 2):S21-S24. ISI | PUBMED 57. Wang S, Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol. 2000;278:F554-F560. FREE FULL TEXT 58. Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int. 2000;57:1002-1014. FULL TEXT | ISI | PUBMED 59. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994;124:96-104. ISI | PUBMED 60. Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor 1 and progression of renal failure. Kidney Int Suppl. 1997;63:S211-S214. PUBMED 61. Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997;23:179-184. ISI | PUBMED 62. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl. 1997;62:S23-S28. PUBMED 63. Aoyama I, Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis. 2001;37(suppl 2):S7-S12. PUBMED 64. Nankivell BJ, Boadle RA, Harris DCH. Iron accumulation in human chronic renal disease. Am J Kidney Dis. 1992;20:580-584. ISI | PUBMED 65. Chen L, Zhang BH, Harris DC. Evidence suggesting that nitric oxide mediates iron-induced toxicity in cultured proximal tubule cells. Am J Physiol. 1998;274(1, pt 2):F18-F25. 66. Tang S, Lai KN, Chan TM, Lan HY, Ho SK, Sacks SH. Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. Am J Kidney Dis. 2001;37:94-103. ISI | PUBMED 67. The GISEN Group (Gruppo Italiano di Studi Epidemiologic in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863. FULL TEXT | ISI | PUBMED 68. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl. 2000;75:S2-S6. FULL TEXT | PUBMED 69. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861-868. ISI | PUBMED 70. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674. ISI | PUBMED 71. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18. FREE FULL TEXT 72. Nomura A, Morita Y, Maruyama S, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol. 1997;151:539-547. ABSTRACT 73. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000;11:700-707. FREE FULL TEXT 74. Bentzel CJ. The filtered complement hypothesis [letter]. Kidney Int. 2000;58:2597-2598. 75. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol. 1999;10:69-76. FREE FULL TEXT 76. Harris RC, Cheng HF. The intrarenal renin-angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol. 1996;4:2-7. 77. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol. 1997;17:412-422. ISI | PUBMED 78. Kennefick TM, Oyama TT, Thompson MM, Vora JP, Anderson S. Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol. 1996;271:F595-F602. 79. Verhagen AMG, Braam B, Boer P, Grone H-J, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int. 1999;56:222-231. ISI | PUBMED 80. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, et al. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 2001;60:2153-2163. FULL TEXT | ISI | PUBMED 81. Dussaule J, Tharaux P, Boffa J, Fakhouri F, Ardaillou R, Chatziantoniou C. Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol. 2000;11:S124-S128. FREE FULL TEXT 82. Yu XQ, Wu LL, Huang XR, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int. 2000;58:1469-1480. FULL TEXT | ISI | PUBMED 83. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension. 2001;37:1171-1178. FREE FULL TEXT 84. Zeisberg M, Strutz F, Muller GA. Renal fibrosis: an update. Curr Opin Nephrol Hypertens. 2001;10:315-320. FULL TEXT | ISI | PUBMED 85. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 2000;58:1389-1399. FULL TEXT | ISI | PUBMED 86. Wolf G, Aberle S, Thaiss F, et al. TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int. 1993;44:795-804. ISI | PUBMED 87. Wolf G, Ziyadeh FN, Thaiss F, et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type 2 receptor. J Clin Invest. 1997;100:1047-1058. ISI | PUBMED 88. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A. 1999;96:10397-10402. FREE FULL TEXT 89. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol. 2001;280:F777-F785. FREE FULL TEXT 90. Wang SN, Lapage J, Hirschberg R. Glomerular ultrafiltrate and apical tubular actions of IGF-1, TGF-, and HGF in nephrotic syndrome. Kidney Int. 1999;56:1247-1251. FULL TEXT | ISI | PUBMED 91. Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG. Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int. 1995;48:45-51. ISI | PUBMED 92. Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664-1676. FULL TEXT | ISI | PUBMED 93. Ruger BM, Hasan Q, Erb KJ, Davis PF. Progression of renal disease in interleukin-4 transgenic mice: involvement of transforming growth factor-. Int J Exp Pathol. 1999;80:113-123. FULL TEXT | ISI | PUBMED 94. Floege J, Burns MW, Alpers CE, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 1992;41:297-309. ISI | PUBMED 95. Terzi F, Burtin M, Friedlander G. Using transgenic mice to analyze the mechanisms of progression of chronic renal failure. J Am Soc Nephrol. 2000;11:S144-S148. FREE FULL TEXT 96. Crook ED. Is there hope for preventing or slowing the progression of chronic renal disease? more support for the role of growth factors. Am J Kidney Dis. 2001;38:652-657. ISI | PUBMED 97. Phillips AO, Topley N, Morrisey K, Williams JD, Steadman R. Basic fibroblast growth factor stimulates the release of pre-formed transforming growth factor-1 from human proximal tubular cells in the absence of de-novo gene transcription or mRNA translation. Lab Invest. 1997;76:591-600. ISI | PUBMED 98. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int. 2001;59:2084-2094. ISI | PUBMED 99. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor- ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 2000;58:2301-2313. FULL TEXT | ISI | PUBMED 100. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001;59:2023-2038. ISI | PUBMED 101. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix deposition by treatment with monoclonal antitransforming growth factor antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97:8015-8020. FREE FULL TEXT 102. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520. 103. Gesualdo L, Ranieri E, Monno R, et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int. 1999;56:461-470. FULL TEXT | ISI | PUBMED 104. Krag S, Osterby R, Chai Q, Nielsen CB, Hermans C, Wogensen L. TGF-1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest. 2000;80:1855-1868. ISI | PUBMED 105. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344. FREE FULL TEXT 106. Sagripanti A, Morganti M, Carpi A, et al. Uremic medium increases cytokine-induced PAI-1 secretion by cultured endothelial cells. Biomed Pharmacother. 1998;52:298-302. FULL TEXT | PUBMED 107. Rerolle J, Hertig A, Nguyen G, Sraer J, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841-1850. FULL TEXT | ISI | PUBMED 108. Arcos MI, Fujihara CK, Sesso A, et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol. 2000;279:F1060-F1066. FREE FULL TEXT 109. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes. 2000;49:500-503. ABSTRACT 110. Lau T, Owen W, Yu YM, et al. Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest. 2000;105:1217-1225. ISI | PUBMED 111. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis. 2001;38(4, suppl 1):S74-S79. ISI | PUBMED 112. Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension. 2001;37:744-748. FREE FULL TEXT 113. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58:1261-1266. FULL TEXT | ISI | PUBMED 114. Schini VB, Durante W, Elizondo E, et al. The induction of nitric oxide synthase activity is inhibited by TGF-1, PDGFAB and PDGFBB in vascular smooth muscle cells. Eur J Pharmacol. 1992;216:379-383. FULL TEXT | ISI | PUBMED 115. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the remnant kidney. J Clin Invest. 1995;96:953-964. 116. Markewitz BA, Michael JR, Kohan DE. Endothelin-1 inhibits the expression of inducible nitric oxide synthase. Am J Physiol. 1997;272(6, pt 1):L1078-L1083. 117. Ikeda M, Ikeda U, Ohkawa F, Shimada K, Kano S. Nitric oxide synthesis in rat mesangial cells induced by cytokines. Cytokine. 1994;6:602-607. FULL TEXT | ISI | PUBMED 118. Berl T, Katz FH, Henric WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978;14:228-235. ISI | PUBMED 119. Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98-101. ISI | PUBMED 120. Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068. ISI | PUBMED 121. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992;41:326-333. ISI | PUBMED 122. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139. FREE FULL TEXT 123. Brown NJ, Nakamura S, Ma LJ, Nakamura I, Donnert E, Freeman M. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000;58:1219-1227. FULL TEXT | ISI | PUBMED 124. Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232-237. FREE FULL TEXT 125. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878. FREE FULL TEXT 126. Ballew JR, Fink GD. Role of endothelin ETB receptor activation in angiotensin II–induced hypertension: effects of salt intake. Am J Physiol Heart Circ Physiol. 2001;281:H2218-H2225. FREE FULL TEXT 127. Park JB, Schiffrin EL. ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37:1444-1449. FREE FULL TEXT 128. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension. 1998;31:10-14. FREE FULL TEXT 129. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 1998;54:353-359. FULL TEXT | ISI | PUBMED 130. Wolf SC, Brehm BR, Gaschler F, et al. Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant. 1999;14(suppl 4):29-30. ISI 131. Ballew JR, Fink GD. Role of ET_A receptors in experimental angiotensin II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R150-R154. FREE FULL TEXT 132. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49:666-678. ISI | PUBMED 133. Tang WW, Ulich TR, Lacy DL, et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial disease. Am J Pathol. 1996;148:1169-1180. ABSTRACT 134. Tang WW, Van GY, Qi M. Myofibroblast and alpha 1(III) collagen expression in experimental tubulointerstitial nephritis. Kidney Int. 1997;51:926-931. ISI | PUBMED 135. Ostendorf T, Kunter U, Groene HJ, et al. Specific antagonism of PDGF prevents renal scaring in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12:909-918. FREE FULL TEXT 136. Miziuri S, Hemmi H, Kumandomidou H, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int. 2001;60:1124-1130. FULL TEXT | ISI | PUBMED 137. Navis G, van der Kleij FGH, de Zeeuw D, de Jong PE. Angiotensin-converting enzyme gene I/D polymorphism and renal disease. J Mol Med. 1999;77:781-791. FULL TEXT | ISI | PUBMED 138. Hunley TE, Julian BA, Phillips JA III, et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996;49:571-577. ISI | PUBMED 139. Penno G, Chafurvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients. Diabetes. 1998;47:1507-1511. FREE FULL TEXT 140. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. Kidney Int. 2000;58:513-519. FULL TEXT | ISI | PUBMED 141. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126-131. ABSTRACT 142. Chuahirun T, Wesson DE. Smoking predicts faster progression of established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis. 2002;39:376-382. ISI | PUBMED 143. Orth SR, Stockmann A, Conradt C, et al. Smoking is a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926-931. FULL TEXT | ISI | PUBMED 144. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis. 2000;35:687-694. ISI | PUBMED 145. Halimi J, Giraudeau B, Vol S, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000;58:1285-1292. FULL TEXT | ISI | PUBMED 146. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism. 1994;43:267-269. FULL TEXT | ISI | PUBMED 147. Ritz E, Orth SR. Adverse effect of smoking on the renal outcome of patients with primary hypertension. Am J Kidney Dis. 2000;35:767-769. ISI | PUBMED 148. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Muliple Risk Factor Intervention Trial. JAMA. 1992;268:3085-3091. FREE FULL TEXT 149. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277:1293-1298. FREE FULL TEXT 150. Hunsicker LG, Adler S, Gaggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908-1919. ISI | PUBMED 151. Ergul S, Ergul A, Hudson JA, et al. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens. 1998;11(11, pt 1):1381-1385. FULL TEXT | ISI | PUBMED 152. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000;97:3479-3484. FREE FULL TEXT 153. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT: Multiple Risk Factor Intervention Trial. JAMA. 1997;278:2069-2074. FREE FULL TEXT 154. Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int. 1992;41:1311-1319. ISI | PUBMED 155. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant. 1995;10:1353-1360. FREE FULL TEXT 156. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51CR-EDTA clearance. Kidney Int. 1991;40:1050-1054. ISI | PUBMED 157. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998;13:1430-1437. FREE FULL TEXT 158. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329:85-89. FREE FULL TEXT 159. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995;25:515-533. ISI | PUBMED 160. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens. 2001;10:219-225. ISI | PUBMED 161. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278-285. FULL TEXT | ISI | PUBMED 162. Zdunek M, Silbiger S, Lei J, Neugarten J. Protein kinase CK2 mediates TGF-1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int. 2001;60:2097-2108. FULL TEXT | ISI | PUBMED 163. Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192-2196. ISI | PUBMED 164. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669-683. FREE FULL TEXT 165. Oda H, Keane WF. Lipids in progression of renal disease. Kidney Int Suppl. 1997;62:S36-S38. FULL TEXT | PUBMED 166. Attman PO, Samuelsson O, Alaupovic P. Progression of renal failure: role of apolipoprotein B-containing lipoproteins. Kidney Int Suppl. 1997;63:S98-S101. FULL TEXT | PUBMED 167. Stevenson FT, Shearer GC, Atkinson DN. Lipoprotein-stimulated mesangial cell proliferation and gene expression are regulated by lipoprotein lipase. Kidney Int. 2001;59:2062-2068. ISI | PUBMED 168. Grone H, Hohbach H, Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl. 1996;54:S18-S22. PUBMED 169. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293-301. FULL TEXT | ISI | PUBMED 170. Washio M, Okuda S, Ikeda M, et al. Hypercholesterolemia and the progression of the renal dysfunction in chronic renal failure patients. J Epidemiol. 1996;6:172-177. PUBMED 171. Yang WQ, Song NG, Ying SS, et al. Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci. 1999;12:104-108. PUBMED 172. Samuelsson O, Attman P, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998;9:1482-1488. ABSTRACT 173. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908-1915. FREE FULL TEXT 174. Perneger TV, Klag MJ, Whelton PK. Recreational drug use: a neglected risk factor for end-stage renal disease. Am J Kidney Dis. 2001;38:49-56. ISI | PUBMED 175. Norris KC, Thornhill-James M, Robinson C, et al. Cocaine use, hypertension, and end-stage renal diease. Am J Kidney Dis. 2001;38:523-528. ISI | PUBMED 176. Lucas SR, Costa Silva VL, Miraglia SM, Zaladek Gil F. Functional and morphometric evaluation of offspring kidney after intrauterine undernutrition. Pediatr Nephrol. 1997;11:719-723. FULL TEXT | ISI | PUBMED 177. Jones SE, Nyengaard JR, Flyvbjerg A, Bilous RW, Marshall SM. Birth weight has no influence on glomerular number and volume. Pediatr Nephrol. 2001;16:340-345. FULL TEXT | ISI | PUBMED 178. Manalich R, Reyes L, Herrera M, Melendi C, Fundora I. Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. Kidney Int. 2000;58:770-773. FULL TEXT | ISI | PUBMED 179. Lackland DT, Egan BM, Fan ZJ, Syddall HE. Low birth weight contributes to the excess prevalence of end-stage renal disease in African Americans. J Clin Hypertens (Greenwich). 2001;3:29-31. 180. Hoy W, Kelly A, Jacups S, et al. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines. Aust N Z J Med. 1999;29:480-483. ISI | PUBMED 181. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJ. Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med. 2000;160:1472-1476. FREE FULL TEXT 182. Law CM, de Swiet M, Osmond C, et al. Intiation of hypertension in utero and its amplication throughout life. BMJ. 1993;306:24-27. 183. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67. FULL TEXT | ISI | PUBMED 184. Phillips DIW, Barker DJP, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37:150-154. FULL TEXT | ISI | PUBMED 185. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis. 1995;25:350-356. ISI | PUBMED 186. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69-75. FREE FULL TEXT 187. Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001;59:876-882. FULL TEXT | ISI | PUBMED 188. Remuzzi G, Benigni A. Repairing renal lesions: will VEGF be the builder? Kidney Int. 2000;58:2594-2595. FULL TEXT | ISI | PUBMED 189. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 2001;37:677-688. ISI | PUBMED 190. Klahr S, Levey A, Beck G, et al, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884. FREE FULL TEXT 191. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis. 1999;34:809-817. ISI | PUBMED 192. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702-709. FULL TEXT | ISI | PUBMED 193. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419. FREE FULL TEXT 194. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of Intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762. FULL TEXT | ISI | PUBMED 195. Peterson JC, Adler SH, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995;123:754-762. FREE FULL TEXT 196. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930. 197. Imanishi M, Yoshioka K, Okumura M, et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int Suppl. 1997;63:S198-S200. PUBMED 198. Benigni A, Tomasoni S, Gagliardini E, et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol. 2001;12:941-948. FREE FULL TEXT 199. Macconi D, Ghilardi M, Bonassi ME, et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol. 2000;11:477-489. FREE FULL TEXT 200. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 2001;44:878-882. FULL TEXT | ISI | PUBMED 201. Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int Suppl. 1997;63:S111-S114. PUBMED 202. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol. 2000;279:F130-F143. FREE FULL TEXT 203. Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999;34:818-823. ISI | PUBMED 204. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming-growth factor-1 in humans. Am J Kidney Dis. 2000;36:894-902. ISI | PUBMED 205. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462. FREE FULL TEXT 206. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792. FULL TEXT | ISI | PUBMED 207. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359-364. FULL TEXT | ISI | PUBMED 208. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Intern Med. 2001;134:370-379. FREE FULL TEXT 209. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160:2645-2650. FREE FULL TEXT 210. Agodoa LY, Appel MD, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized trial. JAMA. 2001;285:2719-2728. FREE FULL TEXT 211. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945. FREE FULL TEXT 212. Apperloo AJ, De Zeeuw D, De Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl. 1994;45:S174-S178. PUBMED 213. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia. 2001;44:883-888. FULL TEXT | ISI | PUBMED 214. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia. 2001;44:874-877. FULL TEXT | ISI | PUBMED 215. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860. FREE FULL TEXT 216. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869. FREE FULL TEXT 217. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878. FREE FULL TEXT 218. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system inpatients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ. 2000;321:1440-1444. FREE FULL TEXT 219. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373-379. FULL TEXT | ISI | PUBMED 220. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-769. FULL TEXT | ISI | PUBMED 221. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis. 2002;39:159-164. ISI | PUBMED 222. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25. ISI | PUBMED 223. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int. 2001;59:2282-2289. ISI | PUBMED 224. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor- levels. Am J Kidney Dis. 2002;39:486-492. ISI | PUBMED 225. Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 2 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890-899. ISI | PUBMED 226. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996;125:201-204. FREE FULL TEXT 227. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-750. FREE FULL TEXT 228. Boero R, Rollino C, Massara C, et al. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol. 2001;14:15-18. ISI | PUBMED 229. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650. ISI | PUBMED 230. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720. FREE FULL TEXT 231. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001;60:1309-1323. FULL TEXT | ISI | PUBMED 232. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431. FREE FULL TEXT 233. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol. 1999;10:2426-2439. FREE FULL TEXT 234. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627-632. FREE FULL TEXT 235. Kasiske BL, Lakatua JDA, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954-961. ISI | PUBMED 236. Walser M, Hill S. Can renal replacement be deferred by a supplemental very low protein diet? J Am Soc Nephrol. 1999;10:110-116. FREE FULL TEXT 237. Aparicio M, Chauveau P, Combe C. Are supplemented low-protein diets nutritionally safe? Am J Kidney Dis. 2001;37(suppl 2):S71-S76. ISI | PUBMED 238. Clinical practice guidelines for nutrition in chronic renal failure: K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000;35(suppl 2):S1-S140. ISI | PUBMED 239. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269. FULL TEXT | ISI | PUBMED 240. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest. 1997;27:997-1002. FULL TEXT | ISI | PUBMED 241. Kim SI, Kim HJ, Han DC, Lee HB. Effect of lovastatin on small GTP binding proteins and on TGF-1 and fibronectin expression. Kidney Int Suppl. 2000;77:S88-S92. FULL TEXT | PUBMED 242. Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001;59:2095-2103. ISI | PUBMED 243. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497-1499, A8. FULL TEXT | ISI | PUBMED 244. Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149. FULL TEXT | ISI | PUBMED 245. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458. FREE FULL TEXT 246. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926. FREE FULL TEXT 247. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808-820. FULL TEXT | ISI | PUBMED 248. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777-784. ISI | PUBMED 249. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-185. ISI | PUBMED 250. Roubicek C, Brunet P, Huiart L, et al. Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis. 2000;36:35-41. ISI | PUBMED 251. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10:1281-1286. FREE FULL TEXT 252. Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis. 2001;38:494-501. ISI | PUBMED 253. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis. 2001;38:1122-1128. ISI | PUBMED 254. Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525-1532. FULL TEXT | ISI | PUBMED 255. Taal MW, Nenov VD, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001;12:2051-2059. FREE FULL TEXT 256. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001;60:715-721. FULL TEXT | ISI | PUBMED 257. Buckingham RE, Al-Barazanji KA, Toseland N, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326-1334. ABSTRACT 258. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001;59:1899-1910. FULL TEXT | ISI | PUBMED 259. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-2139. ABSTRACT 260. Boffa JJ, Tharaux PL, Dussaul JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001;37(pt 2):490-496. FREE FULL TEXT 261. Clozel M, Qiu C, Osterwalder R, et al. Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass. J Cardiovasc Pharmacol. 1999;33:611-618. FULL TEXT | ISI | PUBMED 262. Terzi F, Burtin M, Hekmati M, et al. Targeted expression of a dominant negative epidermal growth factor receptor in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest. 2000;106:225-234. ISI | PUBMED 263. Yang J, Dai C, Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. 2001;8:1470-1479. FULL TEXT | ISI | PUBMED 264. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int. 2001;59:1304-1314. FULL TEXT | ISI | PUBMED 265. Sebekova K, Paczek L, Dammrich J, et al. Effects of protease therapy in the remnant kidney model of progressive renal failure. Miner Electrolyte Metab. 1997;23:291-295. ISI | PUBMED 266. Shimuzu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239-S243. PUBMED 267. Throssell D, Brown J, Furness PN, Rutty G, Walls J, Harris KP. D-penicillamine reduces renal injury in the remnant model of chronic renal failure in the rat. Nephrol Dial Transplant. 1997;12:1116-1121. FREE FULL TEXT 268. Hall AV, Parbtani A, Clark WF, et al. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. Am J Kidney Dis. 1993;22:326-332. ISI | PUBMED 269. Ingram AJ, Parbtani A, Clark WF, et al. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. Am J Kidney Dis. 1995;25:320-329. ISI | PUBMED 270. Ogborn MR, Nitschmann E, Weiler H, Leswick D, Bankovic-Calic N. Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease. Kidney Int. 1999;55:417-423. FULL TEXT | ISI | PUBMED 271. Maddox DA, Alavi FK, Silbernick EM, Zawada ET. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int. 2002;61:96-104. FULL TEXT | ISI | PUBMED 272. Soroka N, Silverberg DS, Greemland M, et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron. 1998;79:173-180. FULL TEXT | ISI | PUBMED 273. Velasquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis. 2001;37:1056-1068. ISI | PUBMED

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chronic Kidney Disease at High Altitude
Luks et al.
J. Am. Soc. Nephrol. 2008;19:2262-2271.
ABSTRACT | FULL TEXT  

How does early chronic kidney disease progress?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease
Metcalfe
Nephrol Dial Transplant 2007;22:ix26-ix30.
FULL TEXT  

Physiological oxygenation status is required for fully differentiated phenotype in kidney cortex proximal tubules
de Laplanche et al.
Am. J. Physiol. Renal Physiol. 2006;291:F750-F760.
ABSTRACT | FULL TEXT  

Inflammatory and Prothrombotic Markers and the Progression of Renal Disease in Elderly Individuals
Fried et al.
J. Am. Soc. Nephrol. 2004;15:3184-3191.
ABSTRACT | FULL TEXT  

Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
Koomans et al.
J. Am. Soc. Nephrol. 2004;15:524-537.
ABSTRACT | FULL TEXT  

Mild Renal Dysfunction and Cardiovascular Risk in Hypertensive Patients
Leoncini et al.
J. Am. Soc. Nephrol. 2004;15:S88-90.
ABSTRACT | FULL TEXT